Screening mammography is provided to women without signs or symptoms of breast disease. Palpable Breast Masses FDG-PET Breast Dedicated There is no relevant literature to support the use of the use of FDG-PET breast dedicated in the initial evaluation of women 30 to 39 years of age with a palpable mass [2]. Image-Guided Core Biopsy Breast There is no relevant literature to support the use of the use of image-guided core biopsy in the initial evaluation of women 30 to 39 years of age with a palpable mass. Image-Guided Fine Needle Aspiration Breast There is no relevant literature to support the use of the use of image-guided FNAB in the initial evaluation of women 30 to 39 years of age with a palpable mass. One study of 1,208 women 30 to 39 years of age presenting with focal breast symptoms found a higher sensitivity for US compared with mammography (95.7% versus 60.9%) but with a similar specificity (89.2% and 94.4%, respectively), negative predictive value (99.9% and 99.2%, respectively), and positive predictive value (13.2% and 18.4%, respectively) [40]. Mammography Screening In women presenting with signs or symptoms, including a palpable breast mass, screening mammography is not useful as the initial imaging study. Screening mammography is provided to women without signs or symptoms of breast disease. MRI Breast There is no relevant literature to support the use of MRI of the breast with or without IV contrast in the initial evaluation of women 30 to 39 years of age with palpable mass [2,23-25]. Sestamibi MBI There is no relevant literature to support the use of Tc-99m sestamibi MBI in the initial evaluation of women 30 to 39 years of age with palpable mass. Supporting Documents The evidence table, literature search, and appendix for this topic are available at https://acsearch. acr.org/list. The appendix includes the strength of evidence assessment and the final rating round tabulations for each recommendation.
Palpable Breast Masses. Screening mammography is provided to women without signs or symptoms of breast disease. Palpable Breast Masses FDG-PET Breast Dedicated There is no relevant literature to support the use of the use of FDG-PET breast dedicated in the initial evaluation of women 30 to 39 years of age with a palpable mass [2]. Image-Guided Core Biopsy Breast There is no relevant literature to support the use of the use of image-guided core biopsy in the initial evaluation of women 30 to 39 years of age with a palpable mass. Image-Guided Fine Needle Aspiration Breast There is no relevant literature to support the use of the use of image-guided FNAB in the initial evaluation of women 30 to 39 years of age with a palpable mass. One study of 1,208 women 30 to 39 years of age presenting with focal breast symptoms found a higher sensitivity for US compared with mammography (95.7% versus 60.9%) but with a similar specificity (89.2% and 94.4%, respectively), negative predictive value (99.9% and 99.2%, respectively), and positive predictive value (13.2% and 18.4%, respectively) [40]. Mammography Screening In women presenting with signs or symptoms, including a palpable breast mass, screening mammography is not useful as the initial imaging study. Screening mammography is provided to women without signs or symptoms of breast disease. MRI Breast There is no relevant literature to support the use of MRI of the breast with or without IV contrast in the initial evaluation of women 30 to 39 years of age with palpable mass [2,23-25]. Sestamibi MBI There is no relevant literature to support the use of Tc-99m sestamibi MBI in the initial evaluation of women 30 to 39 years of age with palpable mass. Supporting Documents The evidence table, literature search, and appendix for this topic are available at https://acsearch. acr.org/list. The appendix includes the strength of evidence assessment and the final rating round tabulations for each recommendation.